In 2014, MAPS spun out a individual division to immediate study and put together for an eventual FDA application, which it submitted at the conclusion of previous year. In early 2024, that offshoot was renamed Lykos Therapeutics. Damage Reduction**: Harm reduction tactics purpose to attenuate the